About Us


International Formulation Business

The International Formulations Business is organized into 3 segments.


1. Emerging Markets 

The Company believes that there are significant growth opportunities in the relevant emerging markets for its exports business. It has finalised geographies in Africa, Asia and CIS countries where it is confident of significant growth opportunities for the next five years and accordingly formulated business plans with own field operations and setting up a strong distributon network for its products.

2. Regulated Markets 

The segment primarily includes sales to US, Europe, Canada, New Zealand and Australia. The business in these markets is classified as

3. Institutional Segment 

The segment involves sale of Company's products pre-qualified by the WHO or the US President's Emergency Plan for AIDS Relief (“PEPFAR”) to global medical institutions or bodies such as United Nations Children's Emergency Fund (“UNICEF”), IDA, GDF, Global Fund, Clinton Foundation, Gates Foundation, Partnership for Supply Chain Management (“PFSCM”) (USA), DFID, UNAID, etc., which fund various global medical programmes


  • Report adverse experiences with medications
  • Report serious adverse reactions. A reaction is serious when the patient outcome is:
    • Death
    • Life-threatening (real risk of dying)
    • Hospitalization (initial or prolonged)
    • Disability (significant, persistent or permanent)
    • Congenital anomaly
    • Required intervention to prevent permanent impairment or damage
  • Report even if:
    • You’re not certain the product caused adverse reaction
    • You don’t have all the details however point nos. 1, 5, 7, 8, 11, 15, 16 & 18 (see reverse) are essentially required.
  • Who can report:
    • Any health care professional (Doctors including Dentists, Nurses and Pharmacists).
  • Where to report:
    • After completing, please return this form to Micro Labs Ltd, Pharmacovigilance Cell
  • What happens to the submitted information:
    • Information provided in this form is handled in strict confidence. PV cell at Micro Labs will carry out causality analysis and the data is statistically analysed and finally submitted to CDSCO.


The patient’s identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter’s identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction.